DMP — Dermapharm Holding SE Income Statement
0.000.00%
Last trade - 00:00
- €1.69bn
- €2.61bn
- €1.14bn
- 50
- 48
- 16
- 28
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 701 | 794 | 943 | 1,025 | 1,135 |
Cost of Revenue | |||||
Gross Profit | 384 | 463 | 621 | 661 | 719 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 581 | 657 | 644 | 781 | 952 |
Operating Profit | 120 | 137 | 298 | 244 | 183 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 110 | 125 | 293 | 216 | 106 |
Provision for Income Taxes | |||||
Net Income After Taxes | 77.8 | 85.9 | 209 | 133 | 60.5 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 77.2 | 85.8 | 210 | 134 | 62.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 77.2 | 85.8 | 210 | 134 | 62.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.57 | 1.86 | 4.19 | 3.27 | 1.66 |